ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
NICE: A Two-Step Non-Invasive Framework for Embryo cfDNA Read Enrichment and Quality Assessment.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Non-invasive preimplantation genetic testing (niPGT) using cell-free DNA (cfDNA) extracted from spent embryo culture medium (SECM) has shown great potential, providing economic and practical advantages for embryo ploidy testing and quality assessment, while minimizing the risk of embryo damage. However, maternal DNA contamination, which can result in sex discordance and false-negative findings, remains a critical barrier to its clinical application in embryo prioritization. In this study, we present the NICE (Non-Invasive CfDNA-based Embryo assessment) framework, designed to enable contamination-resistant evaluation and support accurate embryo selection. The workflow integrates a two-step strategy: first, embryonic cfDNA is effectively purified using DECENT-plus-an enhanced version of our previously established deep CNV reconstruction algorithm (DECENT)-that minimizes interference from polar body-derived maternal DNA and improves signal resolution between maternal and embryonic origins. Subsequently, machine learning models based on biometric features extracted from the purified cfDNA are constructed to classify embryo quality, providing intelligent decision support for clinical embryo prioritization. By addressing the challenge of maternal contamination, NICE establishes a more automated, standardized and non-invasive paradigm for embryo quality assessment and underscores the critical role of cfDNA-based analysis in facilitating non-invasive selection of high-quality embryos to improve outcomes in assisted reproductive technology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.